Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 19;8(12):e70043.
doi: 10.1002/jgh3.70043. eCollection 2024 Dec.

An epidemiological study on the factors including genetic polymorphism influencing ALT >30 U/L and liver fibrosis progression in metabolic dysfunction-associated steatotic liver disease among the general population

Satoshi Sato  1 , Chikara Iino  1 , Takafumi Sasada  1 , Go Soma  1 , Keisuke Furusawa  1 , Kenta Yoshida  1 , Kaori Sawada  2 , Tatsuya Mikami  2 , Shinsaku Fukuda  2 , Shigeyuki Nakaji  2 , Hirotake Sakuraba  1
Affiliations

An epidemiological study on the factors including genetic polymorphism influencing ALT >30 U/L and liver fibrosis progression in metabolic dysfunction-associated steatotic liver disease among the general population

Satoshi Sato et al. JGH Open. .

Abstract

Background and aim: Identifying the factors contributing to the progression of metabolic dysfunction-associated steatotic liver disease (MASLD), a lifestyle-related disease, is crucial for preventing future liver-related deaths. This study aimed to epidemiologically investigate factors, including single-nucleotide polymorphisms (SNPs) associated with alanine aminotransferase (ALT) levels >30 U/L and potential risk factors for liver fibrosis, in a general population cohort of patients with MASLD.

Methods: Among 1059 participants in the health checkup project, 228 who were diagnosed with MASLD were analyzed. Liver fat content and stiffness were measured using FibroScan, and 13 SNPs associated with non-alcoholic fatty liver disease (NAFLD) were measured in addition to other clinical parameters.

Results: In the multivariate analysis, male sex, younger age, and high triglyceride levels were significant risk factors for ALT levels >30 U/L (P-value < 0.05). Furthermore, among the 13 SNPs measured, only the GG genotypes of patatin-like phospholipase domain-containing 3 gene (PNPLA3) rs738409 and rs2896019 were significant risk factors for ALT levels >30 U/L (P-value 0.004 and 0.007). The GG genotypes of PNPLA3 rs738409 and rs2896019 had higher FibroScan-aspartate aminotransferase (FAST) and APRI scores than the CC + CG and TT + TG genotypes (P-value < 0.05). In addition, multivariate analysis revealed that the GG genotypes of rs738409 and rs2896019 were significant risk factors independent of cardiovascular metabolic risk for patients with MASLD (P-value 0.038 and 0.021).

Conclusion: An individualized treatment approach is warranted for patients with MASLD due to the influence of various factors on its progression, including genetic factors and lifestyle diseases.

Keywords: cardiovascular metabolic risk factors; lifestyle; liver fibrosis; metabolic dysfunction‐associated steatotic liver disease; single‐nucleotide polymorphisms.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study enrollment flowchart.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Riazi K, Azhari H, Charette JH et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta‐analysis. Lancet Gastroenterol. Hepatol. 2022; 7: 851–861. - PubMed
    1. Rinella ME, Lazarus JV, Ratziu V et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023; 78: 1966–1986. - PMC - PubMed
    1. LaBrecque DR, Abbas Z, Anania F et al. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2014; 48: 467–473. - PubMed
    1. Keating SE, Hackett DA, George J, Johnson NA. Exercise and non‐alcoholic fatty liver disease: a systematic review and meta‐analysis. J. Hepatol. 2012; 57: 157–166. - PubMed
    1. Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non‐alcoholic steatohepatitis (NASH) and advanced fibrosis in non‐alcoholic fatty liver disease (NAFLD). Liver Int. 2013; 33: 1398–1405. - PubMed

LinkOut - more resources